loader2
Login Open ICICI 3-in-1 Account

Ajanta Pharma Results: Latest Quarterly Results & Analysis

Open Free Trading Account Online with ICICIDIRECT
+91
Ajanta Pharma Ltd. 03 Nov 2025 14:11 PM

Q2FY26 Quarterly Result Announced for Ajanta Pharma Ltd.

Pharmaceuticals company Ajanta Pharma announced Q2FY26 results

  • Revenue from operations at Rs 1,354 crore against Rs 1,187 crore; up 14%.
  • EBITDA at Rs 328 crore against Rs 311 crore; EBITDA at 24%; up 5%.
  • Profit after tax at Rs 260 crore against Rs 216 crore; PAT at 19%; up 20%.
  • The mark-to-market forex loss stood at Rs 41 crore Excluding this impact, EBITDA stood at Rs 369 crore, reflecting a 9% growth, with an EBITDA margin of 27%. PAT grew by 23%, with a PAT margin of 22%.

Result PDF

Pharmaceuticals company Ajanta Pharma announced Q1FY26 results

  • Revenue from operations at Rs 1,303 crore. against Rs 1,145 crore; up 14%.
  • EBITDA at Rs 351 crore. against Rs 330 crore, up 6%; EBITDA at 27%.
  • Profit after tax at Rs 255 crore. against Rs 246 crore; up 4%; PAT at 20%.
  • The mark-to-market forex loss stood at Rs 25 crore. Excluding this impact, EBITDA stood at Rs 376 crore, reflecting a 14% growth, with an EBITDA margin of 29%. PAT grew by 12%, with a PAT margin of 21%.
  • Cashflow from operations (CFO) was Rs 282 crore, EBITDA to CFO conversion of 80%.
  • Free cashflow (FCF) was Rs 209 crore, FCF to PAT conversion of 82%.
  • ROCE stood at a healthy level of 33% and RONW at 26%.

Result PDF

Pharmaceuticals company Ajanta Pharma announced Q4FY25 & FY25 results

Q4FY25 FInancial Highlights:

  • Revenue from operations at Rs 1,170 crore against Rs 1,054 crore; up 11%.
  • EBITDA at Rs 297 crore against Rs 278 crore; up 7%; EBITDA at 25%.
  • Profit after tax at Rs 225 crore against Rs 203 crore; up 11%; PAT at 19%.

FY25 FInancial Highlights:

  • Revenue from operations at Rs 4,648 crore against Rs 4,209 crore; up 10%.
  • EBITDA at Rs 1,260 crore against Rs 1,172 crore; up 7%; EBITDA at 27%.
  • Profit after tax at Rs 920 crore against Rs 816 crore; up 13%; PAT at 20%.
  • Cashflow from operations (CFO) was Rs 1,157 crore, EBITDA to CFO conversion of 92%.
  • Free cashflow (FCF) was Rs 694 crore, FCF to PAT conversion of 75%.
  • ROCE stood at a healthy level of 32% and RONW at 25%.

Result PDF

Pharmaceuticals company Ajanta Pharma announced Q3FY25 results

  • Revenue from operations at Rs 1,146 crore against Rs 1,105 crore; up 4%.
  • EBITDA at Rs 321 crore against Rs 314 crore; up 2%; EBITDA at 28%.
  • Profit after tax at Rs 233 crore against Rs 210 crore; up 11%; PAT at 20%.

Result PDF

Pharmaceuticals company Ajanta Pharma announced H1FY25 & Q2FY25 results

Q2FY25 Financial Highlights:

  • Revenue from operations at Rs 1,187 crore against Rs 1,028 crore; up 15%.
  • EBITDA at Rs 311 crore against Rs 291 crore; up 7%; EBITDA at 26%.
  • Profit after tax at Rs 216 crore against Rs 195 crore; up 11%; PAT at 18%.

H1FY25 Financial Highlights:

  • Revenue from operations at Rs 2,332 crore against Rs 2,049 crore; up 14%.
  • EBITDA at Rs 642 crore against Rs 572 crore; up 12%; EBITDA at 28%.
  • Profit after tax at Rs 462 crore against Rs 403 crore; up 15%; PAT at 20%.
  • Cashflow from operations (CFO) was Rs 776 crore, EBITDA to CFO conversion of 121%.
  • Free cashflow (FCF) was Rs 322 crore, FCF to PAT conversion of 70%.
  • ROCE stood at a healthy level of 34% and RONW at 26%.

Result PDF

Pharmaceuticals company Ajanta Pharma announced Q1FY25 results:

  • Revenue from operations at Rs 1,145 crore against Rs 1,021 crore; up 12%.
  • EBITDA at Rs 330 crore against Rs 271 crore; up 22%; EBITDA at 29%.
  • Profit after tax at Rs 246 crore against Rs 208 crore; up 18%; PAT at 21%.
  • Cashflow from operations (CFO) was Rs 466 crore, EBITDA to CFO conversion of 141%.
  • Free cashflow (FCF) was Rs 301 crore, FCF to PAT conversion of 123%.
  • Shareholders pay-out of Rs 351 crore in June 2024 through buyback of shares at a price of Rs 2,770 per equity share, constituting 0.82% of the total paid-up equity share capital.

Result PDF

Pharmaceuticals company Ajanta Pharma announced Q4FY24 & FY24 results:

Q4FY24 Financial Highlights:

  • Revenue from operations at Rs 1,054 crore against Rs 882 crore; up 20%.
  • EBITDA at Rs 278 crore against Rs 149 crore; up 86%; EBITDA at 26%.
  • Profit after tax at Rs 203 crore against Rs 122 crore; up 66%; PAT at 19%.

FY24 Financial Highlights:

  • Revenue from operations at Rs 4,209 crore against Rs 3,743 crore; up 12%.
  • EBITDA at Rs 1,172 crore against Rs 783 crore; up 50%; EBITDA at 28%.
  • Profit after tax at Rs 816 crore against Rs 588 crore; up 39%; PAT at 19%.
  • Cashflow from operations (CFO) was Rs 785 crore, EBITDA to CFO conversion of 67%.
  • Free cashflow (FCF) was Rs 637 crore, FCF to PAT conversion of 78%.

Result PDF

Pharmaceuticals company Ajanta Pharma announced Q2FY24 & H1FY24 results:

  • Q2FY24:
    • Revenue from operations at Rs 1,028 crore against Rs 938 crore; up 10%.
    • EBITDA at Rs 291 crore against Rs 196 crore; up 48%; EBITDA at 28%.
    • Profit after tax at Rs 195 crore against Rs 157 crore; up 25%; PAT at 19%.
    • Q2FY24, R&D expenses were Rs 50 crore, (Rs 59 crore), 5% of revenue
  • H1FY24:
    • Revenue from operations at Rs 2,049 crore against Rs 1,889 crore; up 8%.
    • EBITDA at Rs 572 crore against Rs 418 crore; up 37%; EBITDA at 28%.
    • Profit after tax at Rs 403 crore against Rs 331 crore; up 22%; PAT at 20%.
    • H1FY24, R&D expenses were Rs 105 crore, (Rs 113 crore), 5% of revenue.

 

Result PDF

Pharmaceuticals company Ajanta Pharma announced Q1FY24 results:

  • Revenue from operations at Rs 1,021 crore in Q1FY24 against Rs 951 crore in Q1FY23; up 7% YoY
  • EBITDA at Rs 271 crore in Q1FY24 against Rs 222 crore in Q1FY23; up 22%; EBITDA at 26% YoY
  • Profit after tax at Rs 208 crore in Q1FY24 against Rs 175 crore in Q1FY23; up 19%; PAT at 20% YoY
  • R&D expenses were Rs 55 crore, 5% of revenue.
  • Board of Directors has approved 1st interim dividend of Rs 315 crore for the year FY24. It translated into Rs 25 per share (1250%) for each Rs 2 face value share.
  • This total dividend of Rs 25 per share includes a regular dividend of Rs 10 per share, and an additional Rs 15 per share, distributed as a special dividend on the commemoration of 50 years of the momentous journey of the Company.

 

 

Result PDF

Ajanta Pharma announced Q4FY23 & FY23 results:

Q4FY23:

  • Revenue from operations at Rs 882 crore against Rs 870 crore; up 1%.
  • EBITDA at Rs 149 crore against Rs 207 crore; EBITDA at 17% of revenue from operations.
  • Profit after tax at Rs 122 crore against Rs 151 crore; PAT at 14% of revenue from operations. 

FY23:

  • Revenue from operations at Rs 3,743 crore against Rs 3,341 crore, up 12%.
  • EBITDA at Rs 783 crore against Rs 929 crore; EBITDA at 21% of revenue from operations.
  • Profit after tax at Rs 588 crore against Rs 713 crore, PAT at 16% of revenue from operations. 

 

Result PDF

Disclaimer – I ICICI Securities Ltd. ( I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is acting as a distributor to solicit bond related products. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein mentioned are solely for informational and educational purpose.
Download App

Download Our App

Play Store App Store
market app